Induction chemotherapy and molecular MRD influence outcomes in KMT2A rearranged AML

Othman, Jad, Potter, Nicola, Freeman, Sylvie D, McCarthy, Nicholas, Jovanovic, Jelena, Runglall, Manohursingh, Canham, Joanna ORCID: https://orcid.org/0000-0003-3482-0990, Thomas, Ian, Johnson, Sean, Gilkes, Amanda, Cavenagh, Jamie, Kottaridis, Panagiotis, Taussig, David, Arnold, Claire, Hemmaway, Claire, Culligan, Dominic, Overgaard, Ulrik Malthe, Dennis, Mike, Burnett, Alan K, Russell, Nigel H and Dillon, Richard 2025. Induction chemotherapy and molecular MRD influence outcomes in KMT2A rearranged AML. Blood 146 (15) , pp. 1862-1867. 10.1182/blood.2025029556 Item availability restricted.

	PDF - Accepted Post-Print Version Restricted to Repository staff only until 6 August 2026 due to copyright restrictions. Download (403kB)
	PDF (Supplemental material/Appendix) - Accepted Post-Print Version Restricted to Repository staff only until 6 August 2026 due to copyright restrictions. Download (2MB)

Abstract

We analyzed 217 patients with KMT2A-rearranged AML in two large sequential randomized trials. Those randomized to FLAG-Ida had markedly lower rates of relapse than other chemotherapy regimens. Molecular MRD assessment after cycle two was strongly prognostic for relapse and death. AML17 ISRCTN55675535 AML19 ISRCTN78449203

Item Type:	Article
Date Type:	Publication
Status:	Published
Schools:	Schools > Medicine Research Institutes & Centres > Centre for Trials Research (CNTRR)
Additional Information:	License information from Publisher: LICENSE 1: Title: This article is under embargo with an end date yet to be finalised.
Publisher:	American Society of Hematology (ASH Publications)
ISSN:	0006-4971
Date of First Compliant Deposit:	9 October 2025
Date of Acceptance:	14 July 2025
Last Modified:	18 Nov 2025 10:15
URI:	https://orca.cardiff.ac.uk/id/eprint/180430

Actions (repository staff only)

Edit Item